Semaglutide is designed to be taken long-term, and for most people, that means indefinitely. The FDA approved Wegovy (the weight loss formulation) for “chronic weight management,” using the same language applied to medications for conditions like high blood pressure or diabetes. There is no built-in end date.
That answer surprises many people, especially those who assumed they’d take it for a year, hit their goal weight, and stop. The reality is more nuanced, and understanding why ongoing treatment is typically necessary can help you plan ahead.
Why Semaglutide Is Considered a Long-Term Medication
Semaglutide works by mimicking a hormone your gut naturally produces after eating. It slows digestion, reduces appetite, and changes signaling in the brain’s hunger centers. But it doesn’t permanently rewire those systems. When the drug leaves your body, the biological drivers of weight regain return.
This is the core reason medical organizations treat obesity the same way they treat type 2 diabetes or hypertension: as a chronic condition that requires ongoing management. Just as blood pressure rises again when you stop a blood pressure medication, the metabolic changes semaglutide produces reverse when you discontinue it. The drug manages the condition rather than curing it.
What Happens When You Stop
A 2025 meta-analysis published in The Lancet tracked weight trajectories after people stopped taking GLP-1 medications like semaglutide. The findings were striking: within one year of stopping, people regained about 60% of the weight they had lost during treatment. The regain wasn’t gradual and steady. It followed a curve, with the fastest rebound happening in the first few months.
This pattern holds even for people who maintained diet and exercise habits after discontinuation. The appetite suppression and metabolic effects of the drug simply aren’t replaced by lifestyle changes alone in most cases. That doesn’t mean stopping is never an option, but it does mean the decision should be made with realistic expectations about what comes next.
The Dose-Escalation Timeline
Before you’re even on the full dose, there’s a structured ramp-up period. For weight management with Wegovy, you start at the lowest dose and increase every four weeks. The standard escalation takes about 16 to 20 weeks before you reach the maintenance dose of 2.4 mg weekly (or 1.7 mg, depending on how you tolerate it). For type 2 diabetes management with Ozempic, the starting dose is 0.25 mg weekly for four weeks, then 0.5 mg, with a possible increase to 1.0 mg based on blood sugar control.
This gradual approach exists to minimize gastrointestinal side effects like nausea, which are most common in the early weeks. Skipping ahead or increasing too quickly tends to make those side effects worse, not speed up results.
Duration for Weight Loss vs. Diabetes
The expected timeline differs depending on why you’re taking semaglutide, though in both cases the medication is meant to continue as long as it’s working.
For weight management, the biggest results typically appear in the first 12 to 18 months, after which weight loss plateaus and shifts into a maintenance phase. The goal then becomes holding onto the progress you’ve made. The FDA label specifically states that Wegovy is intended to “reduce excess body weight and maintain weight reduction long term.”
For type 2 diabetes, semaglutide at the lower Ozempic doses can reduce A1C levels by 1.5 to 1.8 percentage points when added to metformin. Weight loss is more modest, averaging about 8 to 10 pounds. As with weight management, there’s no defined stopping point. If your blood sugar is well controlled on the medication, that’s generally a reason to stay on it, not to stop.
Long-Term Safety Data
One reasonable concern about indefinite use is whether the drug remains safe over years, not just months. The SELECT trial, one of the largest cardiovascular outcome studies for semaglutide, followed patients for over three years. Participants taking semaglutide had a 28% lower rate of major cardiovascular events (heart attack, stroke, or cardiovascular death) compared to placebo. Serious adverse events were actually less frequent in the semaglutide group than the placebo group, regardless of whether patients had heart failure.
The most common ongoing side effects are gastrointestinal: nausea, diarrhea, and constipation. For most people, these improve after the first few months and become manageable on the maintenance dose. A smaller number of people experience more persistent issues that may require dose adjustment.
Can You Taper Off Instead of Stopping Abruptly?
No major medical organization currently recommends a specific tapering protocol for semaglutide. The American Association of Clinical Endocrinology and the American Diabetes Association have not issued formal guidance on how to step down doses.
That said, some clinicians have experimented with gradual dose reduction. In one real-world observational report, patients who tapered over 8 to 12 weeks, stepping down from 2.4 mg to 1.0 mg to 0.5 mg, appeared to have more stable appetite regulation and less psychological distress compared to those who stopped suddenly. The authors were careful to note this is based on clinical experience, not controlled trials, and should be considered preliminary rather than proven. If you’re thinking about discontinuing, this is a conversation to have with whoever prescribes your medication rather than something to attempt on your own schedule.
Staying on a Lower Maintenance Dose
Not everyone needs to remain on the highest dose forever. The FDA label for Wegovy lists both 2.4 mg and 1.7 mg as acceptable maintenance doses, with the choice depending on how well you respond and how you tolerate the medication. Some people find they can step down to a lower dose after reaching their weight loss goals and still maintain most of their progress. This reduces both cost and side effect burden while preserving the drug’s appetite-regulating effects.
This is different from tapering off entirely. A lower maintenance dose still keeps the medication active in your system. It’s a middle ground between the full therapeutic dose and complete discontinuation, and for many people it represents the most practical long-term plan.
Practical Factors That Affect Duration
The clinical evidence points toward indefinite use, but real life introduces complications. Cost is the most obvious one. Without insurance coverage, semaglutide runs over $1,000 per month, and coverage varies widely between plans. Some insurers require documentation of a minimum weight loss percentage (often 5% of body weight) to continue authorizing the prescription, which means your continued access may depend on demonstrating that the drug is working.
Supply shortages have also forced some patients off the medication involuntarily. If you experience an unplanned gap in treatment, the weight regain data suggests acting quickly to resume is better than waiting. Your prescriber may need to restart you at a lower dose to avoid side effects if the gap was more than a few weeks.
Side effects that don’t resolve, changes in your health status, or plans for pregnancy are other legitimate reasons people stop. In each case, the decision involves weighing the benefits of continued treatment against the specific circumstances pushing toward discontinuation, rather than following a fixed timeline.